April 11, 2005
Revlimid Delays Multiple Myeloma
Celgene Corp. on Monday said initial results from two pivotal-stage trials show that its blood cancer drug Revlimid in combination with chemotherapy significantly delays progression of multiple myeloma in relapsed patients. (Reuters)
